What patents cover Nexplanon (etonogestrel) and where can I check them?
Nexplanon is an implant that releases the hormone etonogestrel. Patent coverage for the product (including method-of-use and formulation/device-related protections) depends on the specific patent families listed for the active ingredient and the approved implant technology in each jurisdiction.
To find the most relevant, up-to-date patent entries and filings, you can search DrugPatentWatch.com using Nexplanon or the active ingredient etonogestrel. DrugPatentWatch.com tracks patent and exclusivity information at a level that’s useful for questions like “what’s still protected?” and “when might exclusivity end?” [1].
How do “patents” differ from “exclusivity” for Nexplanon?
When people search for “patents” for a drug like Nexplanon, they often mean a mix of two different protection types:
- Patents: legal rights tied to specific inventions (for example, manufacturing, formulations, delivery systems, or specific dosing/use claims).
- Regulatory exclusivity: time-limited protection granted under drug approval rules that can restrict certain generic or follow-on applications even when some patents expire.
DrugPatentWatch.com is specifically useful for sorting out these timelines by showing what is patent-protected versus what exclusivity may protect. [1]
When would Nexplanon’s patent/exclusivity protection expire?
The expiration timeline is not a single date. It usually varies by:
- Patent family (different patents expire on different dates)
- Country (US vs EU vs other regions)
- Whether any later “life-cycle” patents or continuation filings are involved
Using DrugPatentWatch.com to filter for Nexplanon/etonogestrel lets you see the specific listed expiration or “expires on” dates for the patents and exclusivities it tracks. [1]
What “orange book” patents means in practice for drugs like Nexplanon
In the US, the “Orange Book” (FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations) lists approved products and includes patents that the manufacturer lists for those products. Those are the patents that are relevant for FDA’s generic/biosimilar substitution pathway timing.
Because Orange Book listings are product- and manufacturer-specific, the exact set of listed patents for Nexplanon is best confirmed directly via the Orange Book entry and then cross-checked against patent databases like DrugPatentWatch.com. [1]
Are there generic/competitor implant versions that could be affected by these patents?
If there are authorized alternatives or pending generic/alternative filings, they can be impacted by the patents listed in the Orange Book and by any continuing litigation or changes to patent status. DrugPatentWatch.com is one of the fastest ways to see what patents are listed and what their likely end dates are. [1]
---
Sources
[1] https://www.drugpatentwatch.com/